Celldex Therapeutics, Inc.
Records under this name other than the patents Celldex Therapeutics, Inc. holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned. None of them is counted in the 25 patents it holds.
Back to Celldex Therapeutics, Inc.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 10,668,152 | Use of ANTI-PD-1 Antibody in Combination with ANTI-CD27 Antibody in Cancer Treatment Formerly held In force · Low confidence | In force | Low confidence | |
| US 11,180,566 | Antibodies that bind human CD27 and uses thereof Lapsed on the fee record Ended Nov 23, 2025 · From the USPTO record | Lapsed on the fee record | Ended Nov 23, 2025 | From the USPTO record |
| US 9,649,356 | Method of improving transplant function using soluble complement receptor type I (sCR1) Lapsed on the fee record Ended May 16, 2025 · From the USPTO record | Lapsed on the fee record | Ended May 16, 2025 | From the USPTO record |
| US 9,624,300 | Antibodies that bind human dendritic and epithelial cell 205 (DEC-205) Lapsed on the fee record Ended Apr 18, 2025 · From the USPTO record | Lapsed on the fee record | Ended Apr 18, 2025 | From the USPTO record |
| US 10,745,490 | Anti-Erbb Antibodies and Methods of Use Thereof Formerly held Lapsed on the fee record Ended Aug 18, 2024 · High confidence | Lapsed on the fee record | Ended Aug 18, 2024 | High confidence |
| US 8,236,318 | Antibodies that bind human dendritic and epithelial cell 205 (DEC-205) Lapsed on the fee record Ended Aug 7, 2024 · From the USPTO record | Lapsed on the fee record | Ended Aug 7, 2024 | From the USPTO record |
| US 8,846,873 | Antibodies Directed to Gpnmb and Uses Thereof Lapsed on the fee record Ended Sep 30, 2022 · Medium confidence | Lapsed on the fee record | Ended Sep 30, 2022 | Medium confidence |
| US 8,664,176 | Treatment for age-related macular degeneration and other diseases of the eye Lapsed on the fee record Ended Mar 4, 2022 · From the USPTO record | Lapsed on the fee record | Ended Mar 4, 2022 | From the USPTO record |
| US 8,586,720 | Antibodies that bind human dendritic and epithelial cell 205 (DEC-205) Lapsed on the fee record Ended Nov 19, 2021 · From the USPTO record | Lapsed on the fee record | Ended Nov 19, 2021 | From the USPTO record |
| US 7,563,876 | Human monoclonal antibodies to dendritic cells Formerly held Lapsed on the fee record Ended Jul 21, 2021 · From the USPTO record | Lapsed on the fee record | Ended Jul 21, 2021 | From the USPTO record |